Prudential Financial Inc Verastem, Inc. Transaction History

Prudential Financial Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.02 - $1.83 $331,513 - $594,773	-325,013 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$1.06 - $2.1 $199,110 - $394,464	-187,840 Reduced 36.63%	325,013 $459,000
Q4 2021 Feb 14, 2022	BUY	$2.05 - $3.2 $899,310 - $1.4 Million	438,688 Added 591.5%	512,853 $1.06 Million
Q3 2021 Nov 15, 2021	BUY	$2.54 - $4.07 $157,886 - $252,991	62,160 Added 517.78%	74,165 $228,000
Q2 2021 Aug 16, 2021	SELL	$2.57 - $4.85 $46,982 - $88,662	-18,281 Reduced 60.36%	12,005 $49,000
Q1 2021 May 12, 2021	SELL	$1.9 - $2.82 $6,921 - $10,273	-3,643 Reduced 10.74%	30,286 $75,000
Q4 2020 Feb 16, 2021	BUY	$1.15 - $2.4 $505 - $1,056	440 Added 1.31%	33,929 $72,000
Q3 2020 Nov 16, 2020	BUY	$1.11 - $1.68 $19,940 - $30,179	17,964 Added 115.71%	33,489 $41,000
Q2 2020 Aug 12, 2020	BUY	$1.69 - $4.2 $6,207 - $15,426	3,673 Added 30.99%	15,525 $26,000
Q1 2019 May 15, 2019	BUY	$2.79 - $4.09 $33,067 - $48,474	11,852 New	11,852 $0

297K

Ticker VSTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 210,000,000
Market Cap $983M
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...

Get notified when there are updates to the investment portfolio of Prudential Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Prudential Financial Inc with notifications on news.